SYMMETRY®

Prous Institute is developing the drug discovery platform SYMMETRY aiming to replicate in silico all the real processes through which new drugs are discovered, developed and approved.

Critical components of SYMMETRY include large libraries of compounds generated in silico (see PSMEL) and a wide variety of Chemoinformatic tools.

SYMMETRY® has been designed to keep our minds open to an endless virtual world in which ideas for new drugs can come from anywhere. These ideas can be developed to the point where it is possible to assess success over risk.

Related Links

May 11, 2012

Case Study 2 Now Available: New Approaches to the Discovery of Targeted Therapies II: Discovery of Multitargeted Agents from Medicinal Plants

May 11, 2012

Case Study 1 Now Available: New Approaches to the Discovery of Targeted Therapies I: Discovery of SGLT2 Inhibitors to Control Hyperglycemia in Type 2 Diabetes

Mar 15, 2012

Prous Institute Symmetry® Mutagenicity Model Research Presented at the Society of Toxicology Annual Meeting in San Francisco

Mar 14, 2012

Prous Institute BioEpisteme® delivers encouraging findings from CYP3A4 and CYP2D6 model validation, presented at Society of Toxicology Annual Meeting in San Francisco